This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.
Declaration of Interests
All authors have made a full declaration of interest to the BSH and Task Force Chairs, which may be viewed on request. None of the authors have any relevant conflicts of interest to declare.